REG - Dr. Martens PLC - CFO appointment update

Dr MartensAnnouncement

27/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240227:nRSa5012Ea&default-theme=true

RNS Number : 5012E  Dr. Martens PLC  27 February 2024

 

27 February 2024

Dr. Martens plc

 

CFO appointment update

 

Dr. Martens plc ('the Company') announces that Giles Wilson, who has been
appointed to the role of Chief Financial Officer (CFO), will join the business
and Board on 27(th) May 2024 and will present the FY24 results on 30(th) May
2024.

 

The Company also confirms that Giles and Katie Wilson, a person closely
associated with him, have purchased a total of 57,400 shares in Dr. Martens
plc on the open market since his appointment was first announced.

 

 

 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations
Bethany.Barnes@drmartens.com    +44 7825 187465

Beth Callum, Senior Investor Relations Analyst
Beth.Callum@drmartens.com  +44 203 995 2644

 

Press
 

H/Advisors Maitland
                                +44 207 379 5151

   Katharine Spence
                                +44 7384 535739

 

Gill Hammond, Director of Communications
                                +44 7384 214248

 

 

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire.
Produced originally for workers looking for tough, durable boots, the brand
was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens has since transcended its working-class roots while
still celebrating its proud heritage and, six decades later, "Docs" or "DM's"
are worn by people around the world who use them as a symbol of empowerment
and their own individual attitude. The Company is a constituent of the FTSE
250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZGZZVVDGDZM